{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-043170","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2026-06-15T20:07:28+00:00","discovered_at":"2026-06-15T20:08:00.310339+00:00","generated_at":"2026-06-15T20:08:40.740514+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rhythm posts positive PWS Phase 2 data; MC4R agonist results at ENDO 2026","bullets":["Interim Phase 2 PWS: 17 patients; mean BMI -3.06% at 6 months; 8/10 with moderate-severe hyperphagia improved ≥7 on HQ-CT.","Setmelanotide in acquired HO: -18.9% mean BMI reduction after up to 2.5 years (n=11).","Oral bivamelagon in HO: -16.6% BMI at 1 year for 600 mg dose (n=7).","Real-world BBS: 62% of adults achieved ≥10% body weight loss at 12 months (n=286); reduced outpatient visits (p<0.05).","Company plans Phase 3 development in PWS based on data."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-043170","json":"https://secwatch.observer/filing/0001628280-26-043170.json","markdown":"https://secwatch.observer/filing/0001628280-26-043170.md","text":"https://secwatch.observer/filing/0001628280-26-043170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000162828026043170/0001628280-26-043170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000162828026043170/rytm-20260613.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:08:40.740514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}